From big names such as Google and Anthropic to specialists like Abridge, World Labs, and Mithril, these companies are proving that AI’s ability to solve new problems is hardly tapped out. https://www.fastcompany.com/91495412/artificial-intelligence-most-innovative-companies-2026 Over the past year, tech companies invested hundreds of billions in the new data centers needed to power rapidly increasing demand for the technology. The investment is motivated in part by confidenc

Groundbreaking First-in-Human Study Demonstrates Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression 14-Month Follow-up Data Show Hypoimmune (HIP)-Modified Islets are Safe, Evade Detection by the Immune System, Survive Long-Term, and Continue to Produce Insulin C-Peptide Levels at Month 14 Comparable to Initial Six Months of Study; Results Highlight the Importance of Improved Glycemic Control on Islet Function Full 14-Month Da

Generate Biomedicines has raised $400m in one of the largest biotech initial public offerings (IPO) since 2024, signalling renewed investor appetite for drug developers making the public jump. Generate, an AI drug discovery specialist, has priced 25 million shares at $16 each. The $400m could be bolstered by a further $60m if underwriters exercise their option to buy an additional 3.75 million shares at the same price. Generate’s stock will hit the Nasdaq Global Select Market

Astellas is aiding Vir Biotechnology’s oncology pivot with a $1.7 billion global collaboration focused on a potential best-in-class T-cell engager (TCE) for prostate cancer. Under the leadership of CEO Marianne De Backer, Ph.D., Vir is trading a stake in its PSMA-targeted bispecific VIR-5500 for a $335 million upfront and near-term capital infusion from Astellas. The PSMAxCD3 bispecific leverages Vir’s PRO-XTEN dual-masking technology, which is designed to keep the therapy in

SOMERVILLE, Mass., February 23, 2026 /GLOBE NEWSWIRE/ Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track and Orphan Drug designations to TSRA-196, its lead in vivo gene editing program. TSRA-196 is being jointly developed with Regeneron for the treatment of adults with alpha-1 antitrypsin deficiency (AATD) who are homozygou

SOMERVILLE, Mass., January 12, 2026 /GLOBE NEWSWIRE/ Tessera Therapeutics , the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for TSRA-196, its lead in vivo gene editing therapy for alpha-1 antitrypsin deficiency (AATD). The Company has also received Australian Human Research Ethics Committee (HREC) approval

93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell lymphoma in the 3L+ setting 83% overall response and 61% complete response rates in cohort comprised predominantly of patients with primary refractory large B-cell lymphoma in the 2L setting Manageable safety profile appropriate for outpatient administration; no high-grade CRS and ≤ 5% of patients with Grade ≥ 3 ICANS following dexamethasone pr

Median seizure reduction of 78% through seven months of observation at the third dose level Clinically meaningful gains in multiple measures of neurodevelopment across initial three dose levels, including substantial improvements in cognitive skills by 16 weeks in participants dosed before two years of age Well-tolerated across all four dose levels, with no treatment-related serious adverse events Efficacy data from the fourth dose level and pivotal study initiation expected

Safusidenib demonstrated durable responses, with an ORR of 44% and 88% of patients were progression-free at 24 months Findings supported recent favorable interactions with FDA where alignment was reached on modifying the ongoing G203 into a pivotal trial in high-grade gliomas NEW YORK--(BUSINESS WIRE) -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the publication of positive